Customized Therapeutics LLC Logo
Customized Therapeutics LLC Customized Therapeutics Mission Customized Therapeutics products Customized Therapeutics services About Customized Therapeutics LLC Alliances Our Team Careers Contact Customized Therapeutics LLC

Nano Orb™

The relative ineffectiveness of traditional chemotherapy and the associated side effects have made imperative newer and safer methods of delivering drugs to patients.

The Nano-Orb technology is a Customized Therapeutics' trademarked technology. The multifunctional nano drug delivery systems utilize passive and active targeting to deliver drug payload directly into the tumor cell. The technology also enables tumor detection and allows monitoring of particle accumulation in tumors through external imaging thus providing a valuable diagnostic and therapeutic system.

The Company is collaborating with leading research and academic institutions to develop multifunctional drug delivery platforms based on Super Paramagnetic Iron Oxide Nanoparticles (SPION) and Carbon nanotubes (CNT).

CTNO-S001

The platform based on SPION comprises multilayered polymeric shells and an iron oxide core enabling the carriage of chemotherapeutic agents. The polymeric shells are designed to carry drug(s) with different aqueous solubilities, a critical aspect in chemotherapeutic agent delivery, and include targeting moieties on the surface that specifically target tumor cells. The iron oxide core provides excellent image contrast properties for MRI monitoring as well as for thermal ablation, providing a valuable tool for locating and destroying tumors.

CTL's SPION program is focused on delivering new and existing chemotherapeutic agents for applications in Prostate and Breast cancers.

CTNO-T001

Carbon Nanotubes is a relatively newer area of nanomedicine. The CNT based system is designed with image contrast characteristics suitable for continuos monitoring and to have controllable delivery mechanisms. The drug release is initiated by an external source after confirming the accumulation in tumor cells, significantly improving the therapeutic effect of the drugs and thus reducing any associated side effects. We anticipate that this technology will be useful for intravascular stent-enabled drug delivery to hepatocellular, renal and uterine tumors.